Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 4 Wound Infection 2 Infections 2 Surgical Wound Infection 1 Prostatic Neoplasms 1 Laryngeal Neoplasms 1 Clinical Stage I Cutaneous Melanoma AJCC v8 1 Carcinoma, Hepatocellular 1 Bone Neoplasms 1

Interventions

Docetaxel 277 Prednisone 236 enzalutamide 175 Leuprolide 172 Radiotherapy 164 Abiraterone Acetate 153 Magnetic Resonance Spectroscopy 147 bicalutamide 137 Goserelin 134 Androgen Antagonists 111 Radiosurgery 101 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 100 apalutamide 78 abiraterone 75 gallium 68 PSMA-11 74 Specimen Handling 67 Gonadotropin-Releasing Hormone 58 darolutamide 56 Radiation 56 Triptorelin Pamoate 53 cabazitaxel 49 Zoledronic Acid 49 pembrolizumab 48 Radiotherapy, Intensity-Modulated 47 Flutamide 47 Brachytherapy 47 luprolide acetate gel depot 46 Standard of Care 45 Carboplatin 44 Estramustine 43

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Prostatic Neoplasms × Cefazolin × Clear all

NCT03862170 2025-02-12

BRP30

CR-CSSS Champlain-Charles-Le Moyne

Phase 3 Terminated

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡